← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Haima Therapeutics, Llc
Cleveland, OH
$4,548,197
Total funding
5
Grants
Funding over time
peak $1.1M · FY2018–25$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,374,026 · 3
NSF$1,174,171 · 2
By mechanism
R44$3,074,091 · 2
—$1,174,171 · 2
R43$299,935 · 1
Investigators at Haima Therapeutics, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
SynthoPlate: Intravenous Hemostatic Nanotechnology to Mitigate Bleeding in Thrombocytopenia$994,448
R44 · FY2023 · HL
SynthoPlate: Intravenous Hemostatic Nanotechnology to Mitigate Bleeding in Thrombocytopenia$972,163
R44 · FY2024 · HL
SBIR Phase II: Manufacturing and Characterization of a Synthetic Platelet (SynthoPlateTM) Technology$949,173
· FY2020 · TIP
A Novel Platelet-Inspired Nanotechnology to Restore Hemostasis in Patients on Antiplatelet Agents$944,676
R44 · FY2025 · HL
SynthoPlate: Intravenous Hemostatic Nanotechnology to Mitigate Bleeding in Thrombocytopenia$299,935
R43 · FY2019 · HL
SBIR Phase I: Manufacturing and Characterization of a Synthetic Platelet (SynthoPlateTM) Technology$224,998
· FY2018 · TIP
SynthoPlate: Intravenous Hemostatic Nanotechnology to Mitigate Bleeding in Thrombocytopenia$112,804
R44 · FY2024 · HL
SynthoPlate: Intravenous Hemostatic Nanotechnology to Mitigate Bleeding in Thrombocytopenia$50,000
R44 · FY2025 · HL